$70,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed, from Q4 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to oncology, domestic production of essential drugs, supply chain security, PILLS Act, Biosecure Act and efforts to onshore manufacturing, Loans and grants for biologic production in America Issues related to drug development, oncology, IRA implementation, supply chain security, BIOSECURE as a policy matter, PILLS Act, and domestic production of essential drugs. Strategic National Stockpile of acute radiation syndrome medical counter measures. Administration for Strategic Preparedness & Response."
You can find more data on corporate lobbying on Quiver Quantitative.
CHRS Hedge Fund Activity
We have seen 59 institutional investors add shares of CHRS stock to their portfolio, and 99 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TANG CAPITAL MANAGEMENT LLC removed 2,724,509 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $3,814,312
- TWO SIGMA INVESTMENTS, LP removed 2,259,412 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $2,733,888
- ADAR1 CAPITAL MANAGEMENT, LLC added 1,875,980 shares (+18097.4%) to their portfolio in Q3 2026, for an estimated $2,269,935
- ALYESKA INVESTMENT GROUP, L.P. removed 1,733,234 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $2,097,213
- PROPEL BIO MANAGEMENT, LLC removed 1,420,550 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $1,988,769
- GOLDMAN SACHS GROUP INC added 1,393,394 shares (+231.4%) to their portfolio in Q3 2026, for an estimated $1,686,006
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. removed 1,228,069 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $1,485,963
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
CHRS Analyst Ratings
Wall Street analysts have issued reports on $CHRS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 11/10/2026
- HC Wainwright & Co. issued a "Buy" rating on 10/29/2026
To track analyst ratings and price targets for CHRS, check out Quiver Quantitative's $CHRS forecast page.
CHRS Price Targets
Multiple analysts have issued price targets for $CHRS recently. We have seen 2 analysts offer price targets for $CHRS in the last 6 months, with a median target of $7.5.
Here are some recent targets:
- Paul Jeng from Guggenheim set a target price of $8.0 on 11/10/2026
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $7.0 on 10/29/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.